Drug Trial Radar · NCT02974153
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
Last checked: Nov 20, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,121
Actual
Start
Nov 2016
Primary completion
Nov 2017
Study completion Apr 2018
Sponsor
- Lead sponsor
- Alder Biopharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
Conditions
- Migraine Disorders
Interventions
ALD403 (Eptinezumab)Biological
PlaceboBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Monthly Migraine DaysTime frame: Week 1-12
Locations
144 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Phoenix, Arizona
Research Site
Little Rock, Arkansas
Research Site
Carlsbad, California
Research Site
Oceanside, California
Research Site
Orange, California
Research Site
Oxnard, California
Research Site
Palo Alto, California
Research Site
Redlands, California
Research Site
San Diego, California
Research Site
Santa Monica, California
Research Site
Torrance, California
Research Site
Colorado Springs, Colorado
Research Site
New London, Connecticut
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Tampa, Florida
Research Site
West Palm Beach, Florida
Research Site
Winter Haven, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Champaign, Illinois
Research Site
Chicago, Illinois
Research Site
Chicago, Illinois
Research Site
Anderson, Indiana
Research Site
Des Moines, Iowa
Research Site
Overland Park, Kansas
Research Site
Prairie Village, Kansas
Research Site
Wichita, Kansas
Research Site
Marrero, Louisiana
Research Site
Waldorf, Maryland
Research Site
Boston, Massachusetts
Research Site
North Attleboro, Massachusetts
Research Site
Watertown, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Flowood, Mississippi
Research Site
City of Saint Peters, Missouri
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.